Market Size of Glycobiology Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.62 Billion |
| Market Size (2029) | USD 1.24 Billion |
| CAGR (2024 - 2029) | 14.87 % |
| Fastest Growing Market | Europe |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Glycobiology Market Analysis
The Glycobiology Market size is estimated at USD 0.62 billion in 2024, and is expected to reach USD 1.24 billion by 2029, growing at a CAGR of 14.87% during the forecast period (2024-2029).
Several vaccine development efforts related to COVID-19 primarily focused on the coronavirus transmembrane spike (S) glycoprotein, which extends from the viral surface and mediates host cell entry. A critical step in this crosstalk between the virus and the host cell is the binding of S-glycoprotein to the ACE2 receptor on the surface of human cells. Both S-glycoprotein and ACE2 receptors are known to be extensively glycosylated, i.e., they contain covalently linked complex oligosaccharides called glycans. This makes a promising research path on glycans during the pandemic. Many research studies proved that glycans are crucial in COVID-19 infection. A March 2021 research study by researchers at RIKEN Center for Computational Science (R-CCS) found that glycans sugar molecules play an essential role in the structural changes that occur when the virus causes COVID-19 to invade human cells.
According to a study published in the Journal of Molecular Biology in June 2021, glycan-binding proteins are involved in both human defense and the ability of viruses to infect. Drugs that should be considered for COVID-19 prevention and treatment include glycan antigens, anti-glycan antibodies, glycan-binding proteins, lectin inhibitors, polysaccharides, glycosidase inhibitors, and glycosides. Thus, the above-mentioned factors state that the global glycobiology market was significantly impacted by the COVID-19 pandemic. However, the market is currently gaining its pre-pandemic nature and is expected to witness healthy growth over the forecast period.
The major factor responsible for the growth of the glycobiology market is the increasing research and development activities about glycomes and emerging technology for analyzing glycans and proteomes. Glycans, generally present on the cell surface, play a crucial role in the body system. They are responsible for many hereditary diseases and have a vital role in cancer development. In December 2021, Griffith University's Institute for Glycomics of Australia received a grant of USD 1.80 million from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. In August 2022, GlycoNet, a pan-Canadian network of Centers of Excellence centered at UAlberta, received a USD 10.68 million investment from the Canadian Foundation for Innovation's Major Science Initiative Fund to continue its mission of researching glycomics for the benefit of human health.
Thus, owing to the above-mentioned factors, the market studied is believed to witness strong growth over the forecast period.
